-$0.12 Earnings Per Share Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce earnings of ($0.12) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.07). Conatus Pharmaceuticals reported earnings per share of ($0.17) during the same quarter last year, which indicates a positive year over year growth rate of 29.4%. The company is expected to report its next quarterly earnings results on Wednesday, May 1st.

Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $8.63 million.

Several brokerages recently weighed in on CNAT. Roth Capital reaffirmed a “neutral” rating and set a $1.70 target price on shares of Conatus Pharmaceuticals in a research note on Tuesday, March 26th. HC Wainwright cut Conatus Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $1.50 in a research note on Friday, March 22nd. SunTrust Banks cut Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 4th. Finally, ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Conatus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $5.12.

A number of hedge funds have recently made changes to their positions in CNAT. Two Sigma Investments LP boosted its position in shares of Conatus Pharmaceuticals by 761.1% in the 4th quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after purchasing an additional 221,044 shares during the period. BlackRock Inc. boosted its position in shares of Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares during the period. Hikari Power Ltd acquired a new position in shares of Conatus Pharmaceuticals in the 4th quarter valued at $289,000. Sofinnova Investments Inc. boosted its position in shares of Conatus Pharmaceuticals by 18.4% in the 4th quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 99,282 shares during the period. Finally, Wedbush Securities Inc. acquired a new position in shares of Conatus Pharmaceuticals in the 1st quarter valued at $46,000. 27.41% of the stock is owned by institutional investors and hedge funds.

CNAT stock traded up $0.12 during trading hours on Friday, hitting $0.83. 2,624,833 shares of the stock traded hands, compared to its average volume of 1,736,256. Conatus Pharmaceuticals has a one year low of $0.69 and a one year high of $6.74. The stock has a market capitalization of $25.15 million, a P/E ratio of -1.41 and a beta of 3.27.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.